Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel‐group clinical trial sub‐study
Authors' conclusion
This randomised controlled trial demonstrated that the use of a tubeless AID system improved psychosocial measures to a greater extent than SAP therapy. These results contribute to the growing body of evidence demonstrating that AID may improve quality of life and alleviate some of the burden associated with diabetes self-management in adults with T1D.
Study context
- Population
- Adults aged 18–70 years with T1D
- Comparison
- Tubeless automated insulin delivery (AID) vs sensor augmented pump (SAP) therapy
Methodological detailssub-study, multicentre, parallel-group
- Sub-study
- Multicentre
- Parallel-group
Primary result
As reported in the abstract
Psychosocial outcomes:
- Health-related QoL
- Diabetes impact on QoL
- System usability
- Sleep quality
- Greater score improvements with tubeless AID than SAP for all measures evaluated
- Tubeless AID vs SAP: P = 0.01
- Tubeless AID vs SAP: P = 0.002
- Tubeless AID vs SAP: P = 0.004
- Tubeless AID vs SAP: P < 0.0001
- Tubeless AID vs SAP: P = 0.03
Further findings
INSPIRE scores (tubeless AID only) · baseline and follow-up
- INSPIRE scores high at baseline and follow-up, suggesting positive perceptions of tubeless AID
Original publication
Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel‐group clinical trial sub‐study. Diabetes Obes Metab. Published 8 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →